Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam-Reference-Cited by-同舟云学术

Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam

Published:2018-04 Issue:4 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tamma Pranita D.¹,Fan Yunfan²,Bergman Yehudit³,Sick-Samuels Anna C.¹,Hsu Alice J.⁴,Timp Winston²,Simner Patricia J.³,Prokesch Bonnie C.⁵,Greenberg David E.⁵⁶

Affiliation:

1. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

2. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA

3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

4. Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland, USA

5. Division of Infectious Diseases, University of Texas Southwestern, Dallas, Texas, USA

6. Department of Microbiology, University of Texas Southwestern, Dallas, Texas, USA

Abstract

ABSTRACT We report our clinical experience treating a 2-month-old infant with congenital diaphragmatic hernia who experienced prolonged bacteremia with Burkholderia cepacia complex (Bcc) despite conventional antibiotic therapy and appropriate source control measures. The infection resolved after initiation of ceftazidime-avibactam. Whole-genome sequencing revealed that the isolate most closely resembled B. contaminans and identified the mechanism of resistance that likely contributed to clinical cure with this agent. Ceftazidime-avibactam should be considered salvage therapy for Bcc infections if other treatment options have been exhausted.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02213-17

Reference16 articles.

1. Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in the Emergency Department

2. Centers for Disease Control and Prevention. 25 August 2017. Multistate outbreak of Burkholderia cepacia infections associated with oral liquid docusate sodium. Centers for Disease Control and Prevention, Atlanta, Ga. https://www.cdc.gov/hai/outbreaks/b-cepacia/index.html. Accessed 18 October 2017.

3. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients

4. Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen

5. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing. CLSI, Wayne, PA.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolation and characterization of bacteriophages against Burkholderia species;2024-06-11

2. First case of New Delhi metallo β-lactamase-1 (NDM-1)-producing Burkholderia cepacia complex in Iran;Heliyon;2024-05

3. Species distribution and antimicrobial susceptibility of Burkholderia cepacia complex isolates in clinical infections: Experience from a tertiary care hospital, Southern India;Indian Journal of Medical Microbiology;2024-05

4. In vitro activity of cefiderocol and comparator antibiotics against multidrug-resistant non-fermenting Gram-negative bacilli;JAC-Antimicrobial Resistance;2023-12-28

5. Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review;Microorganisms;2023-07-13